1. Indications and Usage
\nHemostatic Agent:
\nIndicated for the treatment of hemorrhage caused by hyperfibrinolysis (excessive breakdown of blood clots).
\nClinical Scenarios:
\nCommonly used for surgical bleeding (e.g., prostate, thyroid, lung surgeries), obstetric and gynecologic bleeding, hemoptysis (coughing up blood) due to pulmonary tuberculosis, and hematuria (blood in urine).
\n2. Dosage and Administration
\nRoute of Administration:
\nOral administration.
\nAdult Dosage:
\nSingle Dose: 0.25 g to 0.5 g per time.
\nFrequency: 2 to 3 times daily.
\nMaximum Daily Dose: Total daily dose should not exceed 2 g.
\nDuration:
\nDuration should be determined by the physician based on the severity of bleeding.
\n3. Mechanism of Action
\nAntifibrinolytic Activity:
\nAminomethylbenzoic acid is a lysine analog. It acts by competitively inhibiting the binding of plasminogen to fibrin.
\nPhysiological Effect:
\nThis inhibition prevents the activation of plasminogen to plasmin, thereby protecting fibrin clots from degradation by plasmin and achieving hemostasis.
\n4. Safety and Warnings
\nThrombosis Risk:
\nLong-term use or overdose may promote thrombus formation. Use with caution in patients with a history of thromboembolism or a tendency toward thrombosis (e.g., acute myocardial infarction).
\nRenal Impairment:
\nThe drug is excreted via the kidneys. Dosage reduction is recommended for patients with chronic renal insufficiency to prevent accumulation.
\nContraindications:
\nContraindicated in patients with a history of thromboembolic disease or those who are hypersensitive to the drug.
\n5. Adverse Reactions
\nCommon Symptoms:
\nOccasionally causes dizziness, headache, or abdominal discomfort.
\nSerious Risks:
\nOverdose or prolonged use can lead to thrombosis.
\n6. Drug Interactions
\nHormonal Contraceptives & Estrogens:
\nConcurrent use with oral contraceptives or estrogen preparations may increase the risk of thrombosis.
\nCoagulation Factors:
\nShould not be used simultaneously with other coagulation factors (e.g., Factor IX) to avoid excessive thrombosis.
\n7. Pharmaceutical Information
\nChemical Name:
\nAminomethylbenzoic Acid.
\nAppearance:
\nWhite or off-white tablets.
\nStorage:
\nStore in a tightly closed container, protected from moisture.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u963f\u7f8e\u4e50\u00ae\uff08Ameile\u00ae\uff09
\nGeneric Name: Aumolertinib Mesilate
\nStrength: 55mg per tablet (calculated by C\u2083\u2080H\u2083\u2085N\u2087O\u2082), 20 tablets per box
\nManufacturer: Jiangsu Haosen Pharmaceutical Group Co., LTD. (a subsidiary of Hansoh Pharmaceutical)
\nMarketing Authorization Holder: Jiangsu Haosen Pharmaceutical Group Co., LTD.
\nApproval Date in China: March 18, 2020
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 H20200004
\nStorage: Sealed, stored below 30\u2103, away from moisture and direct sunlight, keep out of reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Aumolertinib Mesilate \uff08Ameile\uff09<\/p>\n","protected":false},"featured_media":3270,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27,73],"product_tag":[],"class_list":["post-3268","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","product_cat-chinese-innovative-drug","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n